A5009644458- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 and healthcare impacts
- Palliative Care and End-of-Life Issues
- Healthcare Systems and Technology
- Biosimilars and Bioanalytical Methods
- Chronic Disease Management Strategies
- Nursing Diagnosis and Documentation
- Patient-Provider Communication in Healthcare
- Multiple and Secondary Primary Cancers
- Radiomics and Machine Learning in Medical Imaging
- Cancer survivorship and care
- Healthcare Systems and Public Health
- Advances in Oncology and Radiotherapy
- Clinical practice guidelines implementation
- Telemedicine and Telehealth Implementation
- Global Cancer Incidence and Screening
- Gastric Cancer Management and Outcomes
- Vaccine Coverage and Hesitancy
American Society of Clinical Oncology
2020-2024
Oncology Hematology Care
2018-2021
McKesson (United States)
2018
The US Oncology Network
2018
This report presents the American Society of Clinical Oncology's (ASCO's) evaluation adaptations in care delivery, research operations, and regulatory oversight made response to coronavirus pandemic recommendations for moving forward as recedes. ASCO organized its clinical around five goals ensure lessons learned from COVID-19 experience are used craft a more equitable, accessible, efficient system that protects patient safety, ensures scientific integrity, maintains data quality. The...
The purpose of the Oncology Care Model (OCM) is to improve quality and reduce cost through practice transformation. A foundational tenant avoidable emergency room (ER) visits hospitalizations. In anticipation being an OCM participant, we instituted a multidimensional campaign designed meet these objectives.Prior actions included establishment phone triage unit, after-hours weekend calls, institution urgent care.On basis data from Chronic Condition Warehouse, as provided by Centers for...
Biosimilars offer increased patient choice and potential cost-savings, compared with originator biologics. We studied 3 years of prescribed biologics among US physician practices to determine the relationship practice type payment source oncology biosimilar use.We acquired biologic utilization data from 38 participating in PracticeNET. focused on six (bevacizumab, epoetin alfa, filgrastim, pegfilgrastim, rituximab, trastuzumab) for period 2019 2021. complemented our quantitative analysis a...
The past decade has seen considerable innovation in the delivery of care and payment oncology. Key initiatives have included development oncology medical home standards, Medicare Oncology Care Model, multiple commercial payer initiatives. Looking forward, our next challenge is to reflect on lessons learned from these limited-scale demonstration projects work toward models that are scalable sustainable true collaboration between payers providers sharing common objectives methods advance...
The Survey of Oncology Practice Operations is an annual survey conducted by ASCO since 2016. This the first year in which results have been published publicly for use practice leaders to compare performance their practice. scope 125-question instrument includes medical oncology, radiation drug administration, laboratory, imaging, point-of-care dispensing pharmacy, clinical research, and practice/service-line administration. Benchmarks available include measures staffing, productivity,...
266 Background: Low immunization rates among adults are associated with worse outcomes, particularly immunocompromised individuals, such as those diagnosed a cancer. To better understand vaccination communication and decision-making experiences adult cancer patients treated at safety-net system, we conducted structured interviews to: (1) explore patients’ perceptions of their oncology providers’ role in immunization, (2) the potential factors that underlie hesitancy to receive vaccines....
77 Background: In recent years, several antineoplastic biosimilar products have been approved and marketed for use. We analyzed data from the ASCO PracticeNET learning network to gain insights on adoption of bevacizumab, rituximab, trastuzumab. Methods: Our analysis included following products: bevacizumab-awwb, bevacizumab-bvzr, rituximab (excluding hyaluronidase), rituximab-abbs, trastuzumab, trastuzumab-anns, trastuzumab-dkst, administered July 2019 March 2020. 19 practices submitted...
30 Background: The purpose of the Oncology Care Model is to improve quality and reduce cost through practice transformation. A foundational tenant avoidable ER visits hospitalizations. In anticipation being an OCM participant, we instituted a multidimensional campaign designed meet these objectives. Methods: Prior Actions: Established phone triage unit. After-hours weekend call. Instituted urgent care. Year One: Improved education provided by nurse navigators APPs prior start treatment (OCM...
6542 Background: The purpose of the Oncology Care Model is to improve quality and reduce cost through practice transformation. A foundational tenant avoidable ER visits hospitalizations. In anticipation being an OCM participant, we instituted a multidimensional campaign designed meet these objectives. Methods: Prior Actions: Established phone triage unit. After-hours weekend call. Instituted urgent care. Year One: Improved education provided by nurse navigators APPs prior start treatment...
Abstract Introduction: In response to the need for social distancing and infection prevention during COVID-19 pandemic, there has been increased use of telehealth services manage cancer hematology patients. Throughout March April 2020, Medicare Medicaid programs expanded coverage services, allowing patients receive certain from their home public health emergency. We analyzed data ASCO’s PracticeNET learning network examine reported level-of-service compared standard in-office visits....
Abstract Introduction: During March 2020, as the emergence of COVID-19 began to influence medical and social behaviors in United States, oncology practices reported a disruption normal referral patient management patterns. Participants staff ASCO's PracticeNET learning network sought explore quantify impact this through an analysis activity at multiple hematology/oncology practices. Methods: 20 submitted their billing data for analysis; were located 14 states ranged size from 2 29...
Abstract Background: In April 2020, ASCO initiated a registry to capture and analyze status outcomes of patients with cancer COVID-19, describe effects the pandemic on U.S. practices. Initial findings changes care delivery are included. Methods: Practices provide data due COVID-19 longitudinal confirmed COVID-19. At present, 26 practices have enrolled in Registry—5 academic, 15 hospital/health-system (H/HS) owned, 6 physician-owned (P-O) located 19 states. Enrollment collection is ongoing....
25 Background: In 2016, Medicare added coverage for advance care planning (ACP) services (CPT codes 99497 and 99498). ASCO’s Coverage Reimbursement Steering Group sought to explore quantify whether these are regularly utilized by hematology oncology physicians, provide guidance on administrative best practices successful reimbursement. Methods: We analyzed utilization of management using Physician/Supplier Procedure Summary (2016-2019) Provider Utilization Payment Data: Physician other...